CRBU Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $1.50M; Research and development $18.94M; Operating expenses $26.84M; Income tax (m).
- 2026-03-31: Revenue $2.40M; Research and development $20.61M; Operating expenses $28.68M; Income tax $0.00.
- 2025-12-31: Revenue $3.94M*; Research and development $23.82M*; Operating expenses $32.39M*; Income tax -$550.00K*.
- 2025-09-30: Revenue $2.20M; Research and development $22.40M; Operating expenses $31.60M; Income tax $0.00.
Geography
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Related Party Transactions By Related Party
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Segment
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|
| 2026-06-30 | $1.50M | $18.94M | $26.84M | (m) | -$24.28M |
| 2026-03-31 | $2.40M | $20.61M | $28.68M | $0.00 | -$25.09M |
| 2025-12-31 | $3.94M* | $23.82M* | $32.39M* | -$550.00K* | -$26.49M* |
| 2025-09-30 | $2.20M | $22.40M | $31.60M | $0.00 | -$27.55M |
| 2025-06-30 | $2.67M | $27.69M | $50.24M | (m) | -$54.10M |
| 2025-03-31 | $2.35M | $35.53M | $45.27M | $0.00 | -$39.99M |
| 2024-09-30 | $2.02M | $30.42M | $40.26M | $0.00 | -$34.68M |
| 2024-06-30 | $3.46M | $35.48M | $46.97M | $0.00 | -$37.70M |
| 2024-03-31 | $2.43M | $33.79M | $48.43M | $0.00 | -$41.23M |
| 2023-09-30 | $23.66M | $28.58M | $38.30M | $0.00 | -$10.00M |
| 2023-06-30 | $3.75M | $26.50M | $36.62M | $0.00 | -$29.52M |
| 2023-03-31 | $3.50M | $25.71M | $34.62M | $0.00 | -$28.04M |
| 2022-09-30 | $3.30M | $19.99M | $29.84M | $0.00 | -$26.65M |
| 2022-06-30 | $4.19M | $22.58M | $32.62M | $0.00 | -$26.70M |
| 2022-03-31 | $2.66M | $13.92M | $23.52M | $0.00 | -$19.09M |
| 2021-12-31 | $2.56M | $15.11M | $22.96M | (m) | -$18.48M |
| 2021-09-30 | $3.98M | $15.83M | $22.59M | $0.00 | -$20.97M |
| 2021-06-30 | $1.48M | $12.33M | $17.44M | $0.00 | -$14.31M |
| 2021-03-31 | $1.59M | $10.16M | $14.76M | $0.00 | -$13.16M |
| 2020-12-31 | $984.00K | $12.02M | $16.20M | -$354.00K | -$14.70M |
| 2020-09-30 | $1.20M | $6.18M | $9.43M | -$213.00K | -$7.93M |
| 2020-06-30 | $8.48M | $7.58M | $10.73M | -$50.00K | -$1.87M |
| 2020-03-31 | $1.70M | $8.64M | $12.13M | -$1.20M | -$9.80M |
Revenue and expense 6 month
| Period end | Revenue | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|
| 2026-06-30 | $3.90M | $39.55M | $55.52M | (m) | -$49.37M |
| 2025-06-30 | $5.02M | $63.22M | $95.51M | (m) | -$94.09M |
| 2024-06-30 | $5.89M | $69.27M | $95.40M | $0.00 | -$78.93M |
| 2023-06-30 | $7.26M | $52.21M | $71.24M | $0.00 | -$57.56M |
| 2022-06-30 | $6.86M | $36.50M | $56.14M | $0.00 | -$45.78M |
| 2021-06-30 | $3.06M | $22.49M | $32.20M | $0.00 | -$27.47M |
| 2020-06-30 | $10.18M | $16.22M | $22.86M | -$1.25M | -$11.67M |
Revenue and expense 9 month
| Period end | Revenue | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|
| 2025-09-30 | $7.22M | $85.62M | $127.11M | $0.00 | -$121.64M |
| 2024-09-30 | $7.92M | $99.69M | $135.66M | $0.00 | -$113.61M |
| 2023-09-30 | $30.92M | $80.80M | $109.54M | $0.00 | -$67.56M |
| 2022-09-30 | $10.16M | $56.49M | $85.98M | $0.00 | -$72.43M |
| 2021-09-30 | $7.04M | $37.14M | $53.61M | $0.00 | -$48.44M |
| 2020-09-30 | $11.38M | $22.40M | $32.29M | $1.47M | -$19.61M |
Revenue and expense 12 month
| Period end | Revenue | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|
| 2025-12-31 | $11.16M | $109.44M | $159.50M | -$550.00K | -$148.13M |
| 2024-12-31 | $9.99M | $130.15M | $176.61M | -$9.00K | -$149.10M |
| 2023-12-31 | $34.48M | $112.08M | $150.54M | $193.00K | -$102.07M |
| 2022-12-31 | $13.85M | $82.23M | $120.25M | $70.00K | -$99.42M |
| 2021-12-31 | $9.60M | $52.26M | $76.58M | $321.00K | -$66.92M |
| 2020-12-31 | $12.36M | $34.42M | $48.48M | -$1.82M | -$34.31M |
| 2019-12-31 | $5.79M | $23.64M | $40.09M | -$7.54M | -$23.43M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |